53332-67-5 Usage
General Description
(1-Methyl-1H-imidazol-2-yl)methanamine dihydrochloride is a chemical compound that is commonly used in organic synthesis and pharmaceutical research. It is a white to off-white crystalline powder that is soluble in water and methanol. (1-METHYL-1H-IMIDAZOL-2-YL)METHANAMINE DIHYDROCHLORIDE is known to exhibit both antiviral and antimicrobial properties, making it potentially useful in the development of new drugs for the treatment of infectious diseases. Additionally, it has been studied for its potential role in the treatment of neurological disorders such as epilepsy and schizophrenia. The dihydrochloride salt form of this compound is commonly used to improve its solubility and stability for laboratory and industrial applications. However, it is important to handle this compound with caution, as it may pose health hazards if not used properly.
Check Digit Verification of cas no
The CAS Registry Mumber 53332-67-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,3,3 and 2 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 53332-67:
(7*5)+(6*3)+(5*3)+(4*3)+(3*2)+(2*6)+(1*7)=105
105 % 10 = 5
So 53332-67-5 is a valid CAS Registry Number.
InChI:InChI=1/C5H9N3.2ClH/c1-8-3-2-7-5(8)4-6;;/h2-3H,4,6H2,1H3;2*1H
53332-67-5Relevant articles and documents
2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES
-
Page 74, (2010/02/07)
Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
